You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Adverse event profile

Anoro Ellipta has an adverse event (AE) profile comparable to tiotropium in clinical studies 1 2

Overview of adverse events in the largest comparator study (N=905) 1

Reproduced and adapted from Maleki-Yazdi et al. 2014 1

AE, adverse event; SAE, serious adverse event.

Due to antimuscarinic activity (a LAMA class effect), Anoro Ellipita and tiotropium should be used in caution in patients with urinary retention or narrow angle glaucoma. 3

Cardiovascular events, such as cardiac arrhythmias, may be seen after the administration of muscarinic receptor antagonists and sympathomimetic agents, including umeclidinium/vilanterol. Therefore, Anoro Ellipta should be used with caution in patients with severe cardiovascular disease. 3

This information does not contain all safety information. For a complete description of adverse events, special warnings and precautions, please consult the full SmPC before prescribing this medicine, which you can access by clicking on product SmPC, request from GSK or you can access from the Website of the Pharmaceutical Services of the Ministry of Health

http://www.phs.moh.gov.cy/web/guest/drug-search

References:

  1. Maleki-Yazdi MR et al. Respir Med 2014; 108:1752–1760.
  2. Decramer M et al. Lancet Respir Med 2014; 2:472–486.
  3. Anoro Ellipta SmPC.

 Before prescribing please consult the full SPC which you can request from GSK or access on the website of the Pharmaceutical Services of the Ministry of Health

http://www.phs.moh.gov.cy/web/guest/drug-search 

Trade marks are owned by or licensed to the GSK group of companies. © 2018 GSK group of companies or its licensor.